These drugs are used for a variety of metabolic conditions, most of which are rare, and therefore give very limited opportunity to assess their impact on breastfeeding infants. Some are enzymes which are considered to present little risk to the infant due to gastrointestinal degradation. The risk for other drugs is based on their adverse effect profile in normal adult use and non-human data.